The phase 2, open-label ENACT trial compares the efficacy & safety of enzalutamide monotherapy vs active surveillance in patients with low- or intermediate-risk localized #prostatecancer. ja.ma/3b4YHOH #PCSM #GUCSM

Because of you I am now Twittering...I am a weather vane swayed by the winds of your peer pressure!